Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Deodhar

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|December 4, 2014
Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trialJ Sieper, R Landewé, M Rudwaleit, et al.
The Journal of Rheumatology|April 21, 2007
2006 annual research and education meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN)Muhammad Asim Khan, Daniel O Clegg, Atul A Deodhar, et al.
The Journal of Rheumatology|May 20, 2008
2007 annual research and education meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN)Robert A Colbert, Atul A Deodhar, Muhammad Asim Khan, et al.
RMD Open|October 29, 2015
Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposureP Mease, A Deodhar, R Fleischmann, et al.
JAMA Dermatology|October 1, 2020
Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing SpondylitisBoni E Elewski, John W Baddley, Atul A Deodhar, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 1, 2014
New population-based reference values for spinal mobility measures based on the 2009-2010 National Health and Nutrition Examination SurveyShervin Assassi, Michael H Weisman, MinJae Lee, et al.
Annals of the Rheumatic Diseases|May 22, 2010
Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))P Emery, A Deodhar, W F Rigby, et al.
Annals of the Rheumatic Diseases|September 10, 2013
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 studyR Landewé, J Braun, A Deodhar, et al.
The Journal of Rheumatology|December 3, 2010
Current controversies in spondyloarthritis: SPARTANMichael Weisman, Thomas J Learch, Xenofon Baraliakos, et al.
Annals of the Rheumatic Diseases|April 29, 2022
Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?'Dafna D Gladman, Philip J Mease, Paul Bird, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Arthritis & Rheumatology (Hoboken, N.J.)|December 4, 2014
Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trialJ Sieper, R Landewé, M Rudwaleit, et al.
The Journal of Rheumatology|April 21, 2007
2006 annual research and education meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN)Muhammad Asim Khan, Daniel O Clegg, Atul A Deodhar, et al.
The Journal of Rheumatology|May 20, 2008
2007 annual research and education meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN)Robert A Colbert, Atul A Deodhar, Muhammad Asim Khan, et al.
RMD Open|October 29, 2015
Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposureP Mease, A Deodhar, R Fleischmann, et al.
JAMA Dermatology|October 1, 2020
Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing SpondylitisBoni E Elewski, John W Baddley, Atul A Deodhar, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 1, 2014
New population-based reference values for spinal mobility measures based on the 2009-2010 National Health and Nutrition Examination SurveyShervin Assassi, Michael H Weisman, MinJae Lee, et al.
Annals of the Rheumatic Diseases|May 22, 2010
Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))P Emery, A Deodhar, W F Rigby, et al.
Annals of the Rheumatic Diseases|September 10, 2013
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 studyR Landewé, J Braun, A Deodhar, et al.
The Journal of Rheumatology|December 3, 2010
Current controversies in spondyloarthritis: SPARTANMichael Weisman, Thomas J Learch, Xenofon Baraliakos, et al.
Annals of the Rheumatic Diseases|April 29, 2022
Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?'Dafna D Gladman, Philip J Mease, Paul Bird, et al.
Pageof 10